ASCO CONFERENCE COVERAGE
ASCO CONFERENCE COVERAGE
05/22/2026
Anthony Calabro, MA
In a phase 3 BWEL substudy, a lifestyle-based weight loss intervention improved patient-reported physical function, global health, social roles and activities, and fatigue in women with stage II-III breast...
05/22/2026
Video
Video
05/19/2026
Laura Melaro, DNP, APRN, FNP-BC, PMHCNS-BC
Laura Melaro, DNP, APRN, FNP-BC, PMHNP-BC, previews practical guidance on recognizing, differentiating, and treating anxiety disorders in primary care, including trauma-related conditions, physical symptom...
05/19/2026
Video
Video
05/14/2026
Brittany Albright, MD, MPH
In this video, Brittany Albright, MD, discusses why primary care clinicians are often the first line of defense in recognizing and treating anxiety disorders. She reviews practical strategies for screening,...
05/14/2026
Video
Video
05/13/2026
Rakesh Jain, MD, MPH, RD
Many patients with major depressive disorder remain “stuck” in partial response despite treatment. In this Practical Updates in Primary Care recap, Rakesh Jain, MD, MPH, outlines strategies to identify...
05/13/2026
Research Summary
Research Summary
05/08/2026
Anthony Calabro, MA
An individual participant data meta-analysis clarifies which elements of collaborative care most effectively reduce depressive symptoms in primary care, informing implementation strategies for clinicians...
05/08/2026
Timeline Snapshot
physicians discussing cases
Timeline Snapshot
05/07/2026
April 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
05/07/2026
Research Summary
Research Summary
05/06/2026
Kate Young
A randomized clinical trial in Pakistan evaluated whether structured, measurement-based care could accelerate antidepressant response and remission in adults with major depressive disorder compared with...
05/06/2026
FDA Approval
FDA Approval
04/30/2026
Anthony Calabro, MA
The FDA has approved a supplemental indication for lumateperone to reduce relapse risk in adults with schizophrenia based on phase 3 randomized withdrawal data.
04/30/2026
Research Summary
Research Summary
03/25/2026
Kate Young
In two pragmatic randomized trials conducted in the Capital Region of Denmark, investigators compared collaborative care with consultation liaison in general practice to assess whether greater involvement...
03/25/2026
Research Summary
boy pointing to dermatological condition
Research Summary
03/11/2026
A multinational cross-sectional survey of children and adolescents with moderate-to-severe atopic dermatitis found substantial disease burden, with distinct physical and psychosocial impacts by age group. ...
03/11/2026